Skip to main content
Premium Trial:

Request an Annual Quote

Asterand Extends Research Agreement with Bristol-Myers Squibb

NEW YORK (GenomeWeb News) – Asterand said today that it has extended its drug-discovery and development collaboration with Bristol-Myers Squibb for up to three years.

Under the agreement, BMS will continue to have access to Asterand's PhaseZERO drug-discovery services and XpressBANK human tissue and clinical sample bank for early drug-target validation and compound optimization.

BMS may also use Asterand's ProCURE custom clinical sample collection service, Asterand said.

BMS originally inked a research collaboration with Asterand predecessor Pharmagene in 2001, and the companies have renewed the agreement several times. Pharmagene became a part of Asterand in 2006 through a reverse merger.

Asterand is based in Royston, UK, and Detroit, Michigan, and supplies human tissue and tissue-based services for drug discovery and development.

Filed under

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.